198 related articles for article (PubMed ID: 7657671)
1. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
5. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
6. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
7. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
[TBL] [Abstract][Full Text] [Related]
8. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
9. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.
Argraves KM; Battey FD; MacCalman CD; McCrae KR; Gåfvels M; Kozarsky KF; Chappell DA; Strauss JF; Strickland DK
J Biol Chem; 1995 Nov; 270(44):26550-7. PubMed ID: 7592875
[TBL] [Abstract][Full Text] [Related]
10. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
[TBL] [Abstract][Full Text] [Related]
11. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Bu G; Maksymovitch EA; Schwartz AL
J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
Horn IR; van den Berg BM; van der Meijden PZ; Pannekoek H; van Zonneveld AJ
J Biol Chem; 1997 May; 272(21):13608-13. PubMed ID: 9153209
[TBL] [Abstract][Full Text] [Related]
13. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
14. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.
Mikhailenko I; Considine W; Argraves KM; Loukinov D; Hyman BT; Strickland DK
J Cell Sci; 1999 Oct; 112 ( Pt 19)():3269-81. PubMed ID: 10504332
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
16. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle-dependent fluctuation of urokinase-type plasminogen activator, its receptor, and inhibitors in cultured bovine mammary epithelial and myoepithelial cells.
Zavizion B; White JH; Bramley AJ
Biochim Biophys Acta; 1998 Jun; 1403(2):141-50. PubMed ID: 9630579
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
[TBL] [Abstract][Full Text] [Related]
19. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
[TBL] [Abstract][Full Text] [Related]
20. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
Lee JA; Croucher DR; Ranson M
Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
